Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752826 · ClinicalTrials.gov registry record · Phase 1
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
A Phase 1 study of Ovarian Cancer and Melanoma, sponsored by BioInvent International AB.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT04752826 is a Phase 1 study of Ovarian Cancer and Melanoma that is actively recruiting participants, run by BioInvent International AB. The registered enrollment target is 176 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT04752826, a Phase 1 study of Ovarian Cancer and Melanoma, is actively recruiting participants, sponsored by BioInvent International AB.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizumab every 3 weeks. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors and subjects with T-cell lymphoma (TCL),
Conditions Studied
Interventions
- DRUG BI-1808
- DRUG Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Study Locations (20)
Other
- Rigshospitalet - Copenhagen
- Herlev Hospital - Herlev
- PRA Health Sciences - Hungary - Budapest
- Magyar Honvédség-Egészségügyi Központ - Budapest
- Debreceni Egyetem Klinikai Központ - Debrecen
- Byudzhetnoye Uchrezhdeniye Zdravookhraneniya Omskoy Oblasti - Klinicheskiy Onkologicheskiy Dispanser - Omsk
- National Medical Research Center VA Almazov - Saint Petersburg
- N.N. Petrov National Medical Research Center of Oncology - Saint Petersburg
- Institut Catala d'oncologia. Hospital Duran I Reynals - Barcelona
- Hospital General Universitario Gregorio Marañon - Madrid
- START Madrid - Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Sahlgrenska University Hospital - Gothenburg
- Skanes University Hospital - Lund
- Karolinska University Hospital, Solna - Stockholm
- University Hospital Birmingham - Birmingham
- University Hospitals of Leicester NHS Trust - Leicester
California
- City of Hope National Medical Center - Duarte
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2028-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752826
The ClinicalTrials.gov registry entry for NCT04752826 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The listed sponsor is BioInvent International AB, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which BI-1808 is the first listed.
NCT04752826 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04752826 about?
NCT04752826 is a clinical study titled "BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)". The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-...
What is the current status of trial NCT04752826?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2021-01-25. Estimated completion is 2028-01-15.
What conditions does trial NCT04752826 study?
This clinical trial studies the following conditions: Ovarian Cancer, Melanoma, T-Cell Lymphoma, Advanced Malignancies.
What interventions are being tested in trial NCT04752826?
The interventions under investigation include: BI-1808 (DRUG), Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT04752826?
This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752826 being conducted?
This trial has 20 study locations across California, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.